Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 32 av 32 resultater
Tid
Selskap
Tittel
Sektor
Kategori
24 Oct 2024
07:00 CEST
PHARMING GROUP
Pharming Group reports third quarter 2024 financial results and provides business update
20103015 Pharmaceuticals
Commercial results
10 Oct 2024
08:00 CEST
PHARMING GROUP
Pharming Group to report third quarter 2024 financial results on October 24
20103015 Pharmaceuticals
-
10 Oct 2024
07:00 CEST
PHARMING GROUP
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
20103015 Pharmaceuticals
Products and services
26 Sep 2024
07:00 CEST
PHARMING GROUP
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
20103015 Pharmaceuticals
Products and services
01 Aug 2024
07:00 CEST
PHARMING GROUP
Pharming Group reports second quarter and first half 2024 financial results and provides business update
20103015 Pharmaceuticals
Commercial results
18 Jul 2024
08:00 CEST
PHARMING GROUP
Pharming Group to report second quarter and first half 2024 financial results on August 1
20103015 Pharmaceuticals
Meetings / events
03 Jun 2024
08:00 CEST
PHARMING GROUP
Pharming Group to participate in June investor conferences
20103015 Pharmaceuticals
Meetings / events
30 May 2024
22:44 CEST
PHARMING GROUP
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
20103015 Pharmaceuticals
Products and services
21 May 2024
17:30 CEST
PHARMING GROUP
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
20103015 Pharmaceuticals
General meeting / Board Meeting
20 May 2024
08:00 CEST
PHARMING GROUP
Pharming Group to participate in May investor conference
20103015 Pharmaceuticals
Meetings / events
15 May 2024
07:00 CEST
PHARMING GROUP
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
20103015 Pharmaceuticals
Other financial transaction
08 May 2024
07:00 CEST
PHARMING GROUP
Pharming Group reports first quarter 2024 financial results and provides business update
20103015 Pharmaceuticals
Commercial results
24 Apr 2024
08:00 CEST
PHARMING GROUP
Pharming Group to report first quarter 2024 financial results on May 8
20103015 Pharmaceuticals
Meetings / events
24 Apr 2024
07:00 CEST
PHARMING GROUP
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
20103015 Pharmaceuticals
Other subject
19 Apr 2024
18:43 CEST
PHARMING GROUP
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
20103015 Pharmaceuticals
Other financial transaction
18 Apr 2024
15:04 CEST
PHARMING GROUP
Pharming Group announces the placement of €100 million convertible bonds due 2029
20103015 Pharmaceuticals
Other financial transaction
18 Apr 2024
08:00 CEST
PHARMING GROUP
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
20103015 Pharmaceuticals
Other financial transaction
08 Apr 2024
07:00 CEST
PHARMING GROUP
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
20103015 Pharmaceuticals
Other subject
04 Apr 2024
08:30 CEST
PHARMING GROUP
Pharming Group announces the 2024 Annual General Meeting of Shareholders
20103015 Pharmaceuticals
General meeting / Board Meeting
04 Apr 2024
07:00 CEST
PHARMING GROUP
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
20103015 Pharmaceuticals
Commercial results
03 Apr 2024
08:00 CEST
PHARMING GROUP
Pharming Group to participate in April investor conferences
20103015 Pharmaceuticals
Meetings / events
14 Mar 2024
07:00 CET
PHARMING GROUP
Pharming Group reports fourth quarter and full year 2023 financial results
20103015 Pharmaceuticals
Commercial results
29 Feb 2024
08:00 CET
PHARMING GROUP
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
20103015 Pharmaceuticals
Meetings / events
08 Feb 2024
08:00 CET
PHARMING GROUP
Pharming Group to participate in February investor conferences
20103015 Pharmaceuticals
Meetings / events
08 Jan 2024
07:00 CET
PHARMING GROUP
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
20103015 Pharmaceuticals
Commercial results
13 Dec 2023
07:00 CET
PHARMING GROUP
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
20103015 Pharmaceuticals
Other subject
21 Nov 2023
07:00 CET
PHARMING GROUP
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
20103015 Pharmaceuticals
Other subject
10 Nov 2023
14:51 CET
PHARMING GROUP
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
20103015 Pharmaceuticals
Other subject
01 Nov 2023
08:00 CET
PHARMING GROUP
Pharming Group to participate in November investor conferences
20103015 Pharmaceuticals
-
26 Oct 2023
07:00 CEST
PHARMING GROUP
Pharming Group reports third quarter 2023 financial results
20103015 Pharmaceuticals
Commercial results
12 Oct 2023
08:00 CEST
PHARMING GROUP
Pharming Group to report third quarter 2023 financial results on October 26
20103015 Pharmaceuticals
Meetings / events
25 Sep 2023
16:00 CEST
PHARMING GROUP
Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
20103015 Pharmaceuticals
General meeting / Board Meeting
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva